The limitless future of RNA therapeutics TR Damase, R Sukhovershin, C Boada, F Taraballi, RI Pettigrew, ... Frontiers in bioengineering and biotechnology 9, 628137, 2021 | 388 | 2021 |
Proton pump inhibitors accelerate endothelial senescence G Yepuri, R Sukhovershin, TZ Nazari-Shafti, M Petrascheck, YT Ghebre, ... Circulation research 118 (12), e36-e42, 2016 | 148 | 2016 |
Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation C Boada, A Zinger, C Tsao, P Zhao, JO Martinez, K Hartman, T Naoi, ... Circulation Research 126 (1), 25-37, 2020 | 124 | 2020 |
Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery JO Martinez, R Molinaro, KA Hartman, C Boada, R Sukhovershin, ... Theranostics 8 (4), 1131, 2018 | 96 | 2018 |
Endothelium-derived nitric oxide as an antiatherogenic mechanism: implications for therapy RA Sukhovershin, G Yepuri, YT Ghebremariam Methodist DeBakey cardiovascular journal 11 (3), 166, 2015 | 60 | 2015 |
How may proton pump inhibitors impair cardiovascular health? RA Sukhovershin, JP Cooke American Journal of Cardiovascular Drugs 16, 153-161, 2016 | 50 | 2016 |
mRNA-enhanced cell therapy and cardiovascular regeneration PK Chanda, R Sukhovershin, JP Cooke Cells 10 (1), 187, 2021 | 22 | 2021 |
Local inhibition of macrophage and smooth muscle cell proliferation to suppress plaque progression RA Sukhovershin, NET Furman, E Tasciotti, BH Trachtenberg Methodist DeBakey cardiovascular journal 12 (3), 141, 2016 | 20 | 2016 |
Метиларгинины у крыс в глицериновой модели острой почечной недостаточности МА Гилинский, РИ Айзман, ГА Корощенко, ТВ Латышева, ... Сибирский научный медицинский журнал 30 (4), 82-86, 2010 | 19 | 2010 |
RNA therapeutics for cardiovascular disease C Boada, R Sukhovershin, R Pettigrew, JP Cooke Current opinion in cardiology 36 (3), 256-263, 2021 | 17 | 2021 |
The limitless future of RNA therapeutics. Front. Bioeng. Biotechnol. 9, 628137 TR Damase, R Sukhovershin, C Boada, F Taraballi, RI Pettigrew, ... | 15 | 2021 |
The influence of acute renal injury on arginine and methylarginines metabolism RA Sukhovershin, MA Gilinsky Renal failure 35 (10), 1404-1411, 2013 | 10 | 2013 |
Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics K Wang, F Zhang, C Wen, Z Huang, Z Hu, Y Zhang, F Hu, L Wen Oncology Research 29 (5), 351, 2021 | 6* | 2021 |
Влияние миоглобинурической почечной недостаточности на продукцию оксида азота у крыс РА Суховершин Сибирский научный медицинский журнал 32 (3), 34-38, 2012 | 4 | 2012 |
Methylated arginine analogues: their potential role in atherosclerosis and cognition using the poloxamer-407-induced mouse model of dyslipidemia MA Gilinsky, TP Johnston, NA Zhukova, NI Dubrovina, TV Latysheva, ... Canadian Journal of Physiology and Pharmacology 94 (11), 1122-1131, 2016 | 3 | 2016 |
Endotheliumderived nitric oxide as an antiatherogenic mechanism: implications for therapy. Methodist DeBakey Cardiovasc J 2015; 11 (3): 166-71 RA Sukhovershin, G Yepuri, YT Ghebremariam | 3 | 2015 |
The role of asymmetric dimethylarginine in the regulation of nitric oxide level in rats with acute renal injury RA Sukhovershin, MA Gilinskiĭ Rossiiskii Fiziologicheskii Zhurnal Imeni IM Sechenova 98 (4), 497-505, 2012 | 3 | 2012 |
Cerebral hemodynamic reaction to physical exercise of moderate intensity VP Kulikov, KK Gatal'skiĭ, NL Doronina, K IaA, PA Sukhovershin Rossiiskii Fiziologicheskii Zhurnal Imeni IM Sechenova 93 (2), 161-168, 2007 | 3 | 2007 |
Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery. Theranostics, 2018, 8 (4), 1131-1145 JO Martinez, R Molinaro, KA Hartman, C Boada, R Sukhovershin, ... | 3 | |
Endothelial dysfunction, a major event in atherosclerosis: PPIs impair endothelial function through activation of PAI-1 G Yepuri, R Sukhovershin, TZ Nazari-shafti, YT Ghebremariam, JP Cooke Atherosclerosis 241 (1), e5, 2015 | 2 | 2015 |